Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.
Cornea. 2012 Dec;31(12):1436-40. doi: 10.1097/ICO.0b013e31823f7765.
To report the short-term visual outcomes and complications of keratoprosthesis surgery as the primary penetrating corneal procedure for patients at high risk for conventional corneal transplantation.
A retrospective chart review was conducted of 21 eyes of 19 patients who underwent either Boston keratoprosthesis type I or type II as the primary penetrating corneal procedure from February 2007 to March 2011.
Nineteen type I (90.5%) and 2 type II (9.5%) Boston keratoprosthesis procedures were performed in 19 patients. Mean follow-up was 14.6 months (range, 6-36.3 mo). Primary indications for surgery included chemical or thermal injury, aniridia, and Stevens-Johnson syndrome. Preoperative best-corrected visual acuity (BCVA) ranged from 20/100 to light perception and was count fingers or worse in 20 eyes (95.2%). At last follow-up for all eyes, 15 eyes (71.4%) achieved BCVA≥20/200 and 4 eyes (19%) improved to BCVA≥20/50. No intraoperative complications occurred. Postoperative complications include retroprosthetic membrane formation (47.6%), cystoid macular edema (33.3%), elevated intraocular pressure (23.8%), glaucoma progression (14.3%), and endophthalmitis (4.8%). The initial keratoprosthesis was retained in 19 eyes (90.5%).
The Boston keratoprosthesis, based on early follow-up, is a good alternative as a primary penetrating corneal procedure in a select group of patients with very poor prognosis for penetrating keratoplasty. Although complications can occur and require close monitoring, visual acuity significantly improved in the majority of patients.
报告作为高危患者首选穿透性角膜手术的角膜素移植术的短期视觉结果和并发症。
对 2007 年 2 月至 2011 年 3 月期间接受波士顿角膜素移植术 I 型或 II 型作为主要穿透性角膜手术的 19 名患者的 21 只眼进行回顾性图表分析。
19 名患者进行了 19 例 I 型(90.5%)和 2 例 II 型(9.5%)波士顿角膜素移植术。平均随访时间为 14.6 个月(范围 6-36.3 个月)。手术的主要适应证包括化学或热损伤、无虹膜和史蒂文斯-约翰逊综合征。术前最佳矫正视力(BCVA)范围为 20/100 至光感,20 只眼(95.2%)为手指计数或更差。所有眼末次随访时,15 只眼(71.4%)BCVA≥20/200,4 只眼(19%)改善至 BCVA≥20/50。无术中并发症。术后并发症包括后弹力膜形成(47.6%)、囊样黄斑水肿(33.3%)、眼内压升高(23.8%)、青光眼进展(14.3%)和眼内炎(4.8%)。19 只眼(90.5%)保留了初始角膜素。
基于早期随访,波士顿角膜素移植术是一组预后极差的穿透性角膜移植术患者的首选穿透性角膜手术的良好选择。尽管可能发生并发症且需要密切监测,但大多数患者的视力显著提高。